Scarica l'app Stockscreener
0.9332
11.91%
0.0992
Invivyd Inc Borsa (IVVD) Ultime notizie
New Haven biotech company developing measles treatment as US cases top 2,100 - WFSB
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Value Benchmark - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000E Value Benchmark - marketscreener.com
Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD) - TradingView
IVVD Forecast — Price Target — Prediction for 2027 - TradingView
Invivyd Shareholder Notice - TMX Newsfile
Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd, Inc. (IVVD) reports Q1 loss, lags revenue estimates - MSN
Invivyd Inc (IVVD) Institutional Confidence - TradingKey
IVVDInvivyd Inc Latest SEC Filings - Finviz
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311 - Insider Monkey
INVIVYD INC (IVVD) Stock Chart - ChartMill
Invivyd, Inc. spotlights new data for solid organ transplant recipients in Boston - Traders Union
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd completes Phase 3 COVID-19 antibody trial enrollment - grafa.com
H.C. Wainwright reiterates Invivyd stock rating on trial progress By Investing.com - Investing.com South Africa
Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell - Moomoo
Invivyd completes enrollment in Phase 3 COVID antibody trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com
Invivyd completes enrollment in Phase 3 COVID antibody trial - Investing.com
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - The Manila Times
COVID antibody faces mRNA shots in Phase 3 side-effect study - Stock Titan
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
IVVD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Invivyd, Inc. scrutinizes underexplored link between viral infections and cardiovascular inflammation - Traders Union
IVVD Stock Quote Price and Forecast - CNN
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311 - Contagion Live
Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode - Insider Monkey
Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential - Insider Monkey
IVVD,VCEL Revenue Breakdown - Finviz
IVVD Reiterated by BTIG -- Price Target Maintained at $10 - GuruFocus
Invivyd doses first participants in Phase 3 COVID-19 trial - Yahoo! Finance Canada
Invivyd doses first participants in Phase 3 LIBERTY trial - grafa.com
Small cap wrap: Royal Road Minerals, Miivo Holdings, Alvopetro, Arizona Gold & Silver... - Proactive financial news
Invivyd doses first participants in COVID-19 vaccine trial By Investing.com - Investing.com Australia
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-A - The Manila Times
Invivyd doses first participants in COVID-19 vaccine trial - Investing.com
New COVID shot alternative faces off with mRNA vaccine in Invivyd trial - Stock Titan
InvivydExpects Liberty Trial Topline Data In Q3 2026 - TradingView
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):